LIPOSOME OCULAR DELIVERY SYSTEMS

被引:130
|
作者
MEISNER, D [1 ]
MEZEI, M [1 ]
机构
[1] DALHOUSIE UNIV,COLL PHARM,HALIFAX,NS B3H 3J5,CANADA
关键词
DRUG DELIVERY; LIPOSOME; OPHTHALMOLOGY; OCULAR; TOPICAL INSTILLATION; SUBCONJUNCTIVAL INJECTION; INTRAVITREAL INJECTION; SYSTEMIC ADMINISTRATION;
D O I
10.1016/0169-409X(95)00016-Z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Liposomes are microscopic vesicles composed of membrane-like lipid bilayers surrounding aqueous compartments. This unique feature imparts the ability of liposomes to encapsulate both lipophilic and hydrophilic compounds. Consequently liposomes have been investigated extensively as a drug carrier system by various routes of administration. One of the more recent applications is the concept of employing liposomes as drug carriers in ophthalmology. Traditional drug therapy in the eye consists of the administration of solutions and suspensions. These dosage forms are compromised in their effectiveness by several limitations including rapid nasolacrimal drainage, poor corneal penetration, nonproductive conjunctival losses and unwanted systemic exposure. The need for an ocular drug delivery system which has the convenience of a drop, but will localize and maintain drug activity at its site of action, is apparent. Liposomes offer a promising avenue to achieve this goal. The simplicity of preparation and the versatility in physical characteristics confer a unique and useful property to liposomes for use as an ocular drug deliverer. In this review, a historical account of the studies is presented to illustrate the potential of liposomes in ophthalmology. Consideration is given to methods of preparation, advantages of liposomes as drug carriers as well as some of the general issues surrounding liposomes as a pharmaceutically acceptable dosage form. Various routes of administration such as topical instillation, intravitreal, subconjunctival and systemic injection are also discussed. Significant progress has been made in these areas and a complete understanding of the liposome interaction with ocular tissues should enable the design of liposomal products suitable for ocular drug delivery.
引用
收藏
页码:75 / 93
页数:19
相关论文
共 50 条
  • [1] LIPOSOME DELIVERY SYSTEMS CONTAINING IBUPROFEN
    BULA, D
    GHALY, ES
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1995, 21 (14) : 1621 - 1629
  • [2] Liposome-based drug delivery systems
    Langner, M
    Kral, TE
    POLISH JOURNAL OF PHARMACOLOGY, 1999, 51 (03): : 211 - 222
  • [3] GROUNDBREAKING DELIVERY SYSTEMS: LIPOSOME -MICROBUBBLES COMPLEXES
    Dwivedi, Pankaj
    JOURNAL OF RESEARCH IN PHARMACY, 2023, 27
  • [4] Trends and developments in liposome drug delivery systems
    Lian, T
    Ho, RJY
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (06) : 667 - 680
  • [6] Characterization of microencapsulated liposome systems for the controlled delivery of liposome-associated macromolecules
    Machluf, M
    Regev, O
    Peled, Y
    Kost, J
    Cohen, S
    JOURNAL OF CONTROLLED RELEASE, 1997, 43 (01) : 35 - 45
  • [7] Rebamipide liposome as an effective ocular delivery system for the management of dry eye disease
    Qiao, Han
    Xu, Zhuo
    Sun, Mengchi
    Fu, Shuwen
    Zhao, Fangxue
    Wang, Danping
    He, Zhonggui
    Zhai, Yinglei
    Sun, Jin
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2022, 75
  • [8] TREATMENT OF OCULAR MELANOMA BY LIPOSOME-TARGETED DRUG DELIVERY IN COMBINATION WITH HYPERTHERMIA
    VO, KD
    KHOOBEHI, B
    PEYMAN, GA
    GOLSHANI, R
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1992, 33 (04) : 729 - 729
  • [9] Advances in ocular drug delivery systems
    Kang-Mieler, Jennifer J.
    Rudeen, Kayla M.
    Liu, Wenqiang
    Mieler, William F.
    EYE, 2020, 34 (08) : 1371 - 1379
  • [10] Advances in Ocular Drug Delivery Systems
    Silva-Cunha, Armando
    PHARMACEUTICS, 2021, 13 (09)